Willem L. Bor

774 total citations
20 papers, 121 citations indexed

About

Willem L. Bor is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Willem L. Bor has authored 20 papers receiving a total of 121 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cardiology and Cardiovascular Medicine, 8 papers in Surgery and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Willem L. Bor's work include Antiplatelet Therapy and Cardiovascular Diseases (14 papers), Acute Myocardial Infarction Research (9 papers) and Atrial Fibrillation Management and Outcomes (7 papers). Willem L. Bor is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (14 papers), Acute Myocardial Infarction Research (9 papers) and Atrial Fibrillation Management and Outcomes (7 papers). Willem L. Bor collaborates with scholars based in Netherlands, United States and United Kingdom. Willem L. Bor's co-authors include Jurriën M. ten Berg, Arnoud W.J. van ‘t Hof, Leo Timmers, Hans van den Berg, Joyce Peper, Martin J. Swaans, Diana A. Gorog, Barry S. Coller, Ohad S. Bentur and Vincent J. Nijenhuis and has published in prestigious journals such as European Heart Journal, American Heart Journal and Frontiers in Pharmacology.

In The Last Decade

Willem L. Bor

19 papers receiving 121 citations

Peers

Countries citing papers authored by Willem L. Bor

Since Specialization

Citations

This map shows the geographic impact of Willem L. Bor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willem L. Bor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willem L. Bor more than expected).

Fields of papers citing papers by Willem L. Bor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willem L. Bor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willem L. Bor. The network helps show where Willem L. Bor may publish in the future.

Co-authorship network of co-authors of Willem L. Bor

This figure shows the co-authorship network connecting the top 25 collaborators of Willem L. Bor. A scholar is included among the top collaborators of Willem L. Bor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willem L. Bor. Willem L. Bor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The impact of stroke and bleeding on mortality and quality of life during the first year after TAVI: A POPular TAVI subanalysis 2024 ·Catheterization and Cardiovascular Interventions ·(unknown), (unknown), (unknown), Willem L. Bor, Jorn Brouwer, Vincent J. Nijenhuis, Joyce Peper, Arnoud W.J. van ‘t Hof, Pieter A. Vriesendorp, Jurriën M. ten Berg	0
2	Postoperative Myocardial Injury and Inflammatory Biomarkers in Patients Undergoing Vascular Surgery: A Subanalysis of the Platelet Reactivity and Postoperative Myocardial Injury after Major Vascular Surgery (PROMISE) Study 2023 ·Annals of Vascular Surgery ·(unknown), Willem L. Bor, Johannes C. Kelder, C. M. Hackeng, R.H. Kropman, Jurriën M. ten Berg, Peter G. Noordzij	1
3	Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction – A post hoc analysis of the cel-02 phase IIa study 2023 ·American Heart Journal ·(unknown), Willem L. Bor, (unknown), (unknown), (unknown), C. Michael Gibson, Christopher B. Granger, Ohad S. Bentur, Barry S. Coller, Arnoud W.J. van ‘t Hof, Jurriën M. ten Berg	7
4	Quality of Life Measures in Aortic Stenosis Research: A Narrative Review 2023 ·Cardiology ·Derk Frank, Simon Kennon, Nikolaos Bonaros, Mauro Romano, Carlo Di Mario, (unknown), Willem L. Bor, Markus Kasel, Ole De Backer, (unknown), (unknown), Jana Kurucova, Peter Bramlage, Rima Styra	2
5	Diagnostic Performance of CCTA and CT-FFR for the Detection of CAD in TAVR Work-Up 2022 ·JACC: Cardiovascular Interventions ·Joyce Peper, (unknown), Hans van den Berg, Willem L. Bor, Jorn Brouwer, Vincent J. Nijenhuis, (unknown), Benno Rensing, Jurriën M. ten Berg, Leo Timmers, Tim Leiner, Martin J. Swaans	31
6	Hemostatic biomarkers and antithrombotic strategy in percutaneous left atrial interventions: State-of-the-art review 2022 ·Thrombosis Research ·(unknown), (unknown), Willem L. Bor, Moniek Maarse, (unknown), Hugo Ten Cate, Jurriën M. ten Berg, Lucas V.A. Boersma	5
7	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial 2022 ·EuroIntervention ·Bastiaan Zwart, Willem L. Bor, (unknown), (unknown), (unknown), (unknown), Deepak L. Bhatt, (unknown), (unknown)	5
8	Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study 2022 ·EuroIntervention ·Willem L. Bor, (unknown), (unknown), (unknown), (unknown), (unknown), Mathias Vrolix, Martijn Meuwissen, (unknown), Carlos Van Mieghem, Michael Magro, (unknown), (unknown), Tom Adriaenssens, Willem Dewilde, (unknown)	2
9	Postoperative myocardial injury and platelet reactivity in patients undergoing vascular surgery: The platelet reactivity and postoperative myocardial injury after major vascular surgery (PROMISE) study 2022 ·Thrombosis Research ·(unknown), Willem L. Bor, Lisette M. Vernooij, (unknown), Johannes C. Kelder, C. M. Hackeng, R.H. Kropman, Jurriën M. ten Berg, Peter G. Noordzij	2
10	Effects of CYP3A422 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study 2022 ·Frontiers in Pharmacology* ·(unknown), Thomas O. Bergmeijer, (unknown), Dean R.P.P. Chan Pin Yin, (unknown), Joyce Peper, Willem L. Bor, Daniel M.F. Claassens, Ron H. N. van Schaik, Jurriën M. ten Berg	2
11	Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation 2022 ·European Journal of Internal Medicine ·(unknown), Willem L. Bor, Leo Veenstra, Arnoud W.J. van ‘t Hof, Enrico Fabris	9
12	The WOEST 2 registry 2022 ·Netherlands Heart Journal ·(unknown), (unknown), Willem L. Bor, JEAN PAUL HERRMAN, Mathias Vrolix, Martijn Meuwissen, (unknown), Tom Adriaenssens, Bernard De Bruyne, Michael Magro, Willem J.M. Dewilde, J M Ten Berg	2
13	Diagnostic performance of coronary CTA and CT-FFR for the detection of coronary artery disease in routine TAVI work-up 2022 ·European Heart Journal ·Joyce Peper, (unknown), Hans van den Berg, Willem L. Bor, Jorn Brouwer, Vincent J. Nijenhuis, (unknown), (unknown), (unknown), J. M. ten Berg, Tim Leiner, Martin J. Swaans	1
14	A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. 2022 ·PubMed ·Bastiaan Zwart, Willem L. Bor, (unknown), Bakhtawar K. Mahmoodi, Johannes C. Kelder, Gregory Y.H. Lip, Deepak L. Bhatt, Christopher P. Cannon, Jurriën M. ten Berg	4
15	Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry 2021 ·BMC Cardiovascular Disorders ·(unknown), (unknown), Willem L. Bor, (unknown), Saman Rasoul, E. Kaplan, Koen Teeuwen, Sjoerd H. Hofma, Erik Lipšic, Giovanni Amoroso, (unknown), Jurriën M. ten Berg, Arnoud W.J. van ‘t Hof, Rik Hermanides	2
16	Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction 2021 ·EuroIntervention ·Willem L. Bor, (unknown), (unknown), C. Michael Gibson, Christopher B. Granger, Ohad S. Bentur, (unknown), Sonja Postma, Barry S. Coller, Arnoud W.J. van ‘t Hof, Jurriën M. ten Berg	25
17	Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry 2021 ·European Heart Journal Open ·(unknown), (unknown), Willem L. Bor, (unknown), Saman Rasoul, E. Kaplan, Koen Teeuwen, Sjoerd H. Hofma, Erik Lipšic, Giovanni Amoroso, (unknown), J M Ten Berg, Arnoud W.J. van ‘t Hof, Renicus S. Hermanides	3
18	Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards “Personalized Medicine” in Daily Clinical Practice 2020 ·Journal of Clinical Medicine ·Dean R.P.P. Chan Pin Yin, (unknown), (unknown), (unknown), Melvyn Tjon Joe Gin, (unknown), (unknown), Daniel M.F. Claassens, Marieke E. Gimbel, (unknown), Willem L. Bor, Tom Oirbans, (unknown), Georgios J. Vlachojannis, Rutger J. van Bommel, Yolande Appelman, José P.S. Henriques, Wouter J. Kikkert, Jurriën M. ten Berg	8
19	Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial 2020 ·Journal of Clinical Medicine ·Marieke E. Gimbel, (unknown), Willem L. Bor, Renicus S. Hermanides, (unknown), Ton A.C.M. Heestermans, Melvyn Tjon Joe Gin, Reinier A. Waalewijn, Sjoerd H. Hofma, Frank den Hartog, J. Wouter Jukema, Clemens von Birgelen, Michiel Voskuil, Johannes C. Kelder, Vera H.M. Deneer, Jurriën M. ten Berg	5
20	Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome 2020 ·Journal of Clinical Medicine ·Willem L. Bor, Diana A. Gorog	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact